There are 2789 resources available
Invited Discussant LBA23 and 512O
Presenter: Christophe Massard
Session: Proffered Paper session - Developmental therapeutics
Resources:
Slides
Webcast
No
Presenter: Yelena Janjigian
Session: Chemoradiotherapy should be the standard to maximize cure in localised esophagogastric junction cancer
Resources:
Slides
Webcast
Polling 2 (led by chair)
Presenter: Florian Lordick
Session: Chemoradiotherapy should be the standard to maximize cure in localised esophagogastric junction cancer
Resources:
Slides
Webcast
Q&A
Presenter: Florian Lordick
Session: Chemoradiotherapy should be the standard to maximize cure in localised esophagogastric junction cancer
Resources:
Slides
Webcast
Introduction by the chair
Presenter: Florian Lordick
Session: Chemoradiotherapy should be the standard to maximize cure in localised esophagogastric junction cancer
Resources:
Slides
Webcast
Yes
Presenter: John Reynolds
Session: Chemoradiotherapy should be the standard to maximize cure in localised esophagogastric junction cancer
Resources:
Slides
Webcast
Invited Discussant VP3_2021
Presenter: Pasi Jänne
Session: Virtual Plenary Debate
Resources:
Slides
Webcast
VP3_2021 - A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial
Presenter: Ross Soo
Session: Virtual Plenary Debate
Resources:
Abstract
Slides
Webcast
VP7_2021 - KEYNOTE-522: Phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy as neoadjuvant treatment, followed by pembrolizumab vs placebo as adjuvant treatment for early triple-negative breast cancer (TNBC)
Presenter: Peter Schmid
Session: Virtual Plenary Debate
Resources:
Abstract
Slides
Webcast
Invited Discussant VP2_2021
Presenter: Marina Chiara Garassino
Session: Virtual Plenary Debate
Resources:
Slides
Webcast